Use of Allograft Adipose Matrix for Small Joint Arthritis of the Hand

Launched by CEDARS-SINAI MEDICAL CENTER · Feb 16, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment option for people with early-stage osteoarthritis in their hand joints. Specifically, it is testing the safety and effectiveness of injecting a special type of tissue called adipose allograft matrix (AAM) directly into the small joints of the hand. The researchers believe that this injection could help reduce pain and improve function without the risks associated with some current treatments, such as using a patient’s own fat.

To participate in this study, you need to be over 18 years old and have hand joint pain along with medical imaging showing signs of osteoarthritis. However, if you have had previous treatments for your hand pain, certain health conditions, or are pregnant or breastfeeding, you may not be eligible. Participants will first complete some surveys and tests to assess their pain and ability to move, and then they will receive the AAM injection during a separate visit. The trial is currently recruiting participants, and everyone is welcome to apply.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients greater than 18 years, with presentation to the Cedars Sinai hand clinic for joint pain of the hand carpometacarpal, interphalangeal, proximal interphalangeal, and distal interphalangeal joints (CMC, IP, PIP or DIP joints).
• • Radiographic evidence of osteoarthritis.
• Exclusion Criteria:
• • Prior intervention for the presenting joint (either in the form of cortisone or hyaluronic acid injection or surgery).
• • Rheumatoid or other inflammatory arthritis condition
• • Collagen vascular disease
• • Pregnancy or breast-feeding
• • Congestive heart failure
• • Chronic obstructive pulmonary disease
• • Chronic renal failure
• • Those who had medication or oral supplements for the previous 4 weeks that could prolong bleeding time (e.g.; Aspirin, Plavix).